Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Human Papillomavirus | Review

B cells in head and neck squamous cell carcinoma: current opinion and novel therapy

Authors: Xinyue Guo, Licheng Xu, Luan Nie, Chenyu Zhang, Yaohui Liu, Rui Zhao, Jing Cao, Linli Tian, Ming Liu

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumour. Despite advancements in surgery, radiotherapy and chemotherapy, which have improved the prognosis of most patients, a subset of patients with poor prognoses still exist due to loss of surgical opportunities, postoperative recurrence, and metastasis, among other reasons. The tumour microenvironment (TME) is a complex organization composed of tumour, stromal, and endothelial cells. Communication and interaction between tumours and immune cells within the TME are increasingly being recognized as pivotal in inhibiting or promoting tumour development. Previous studies on T cells in the TME of HNSCC have yielded novel therapeutic possibilities. However, the function of B cells, another adaptive immune cell type, in the TME of HNSCC patients has yet to be determined. Recent studies have revealed various distinct subtypes of B cells and tertiary lymphoid structures (TLSs) in the TME of HNSCC patients, which are believed to impact the efficacy of immune checkpoint inhibitors (ICIs). Therefore, this paper focuses on B cells in the TME to explore potential directions for future immunotherapy for HNSCC.
Literature
1.
2.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global Cancer Statistics 2020. GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
3.
Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233:780–6.PubMedPubMedCentralCrossRef
4.
Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19:306–27.PubMedPubMedCentralCrossRef
5.
Li S, Wang Y, Sun R, Franceschi D, Pan H, Wei C, Ogbuehi AC, Lethaus B, Savkovic V, Gaus S, Zimmerer R, Ziebolz D, Schmalz G, Jiang X. Single-Cell Transcriptome Analysis Reveals Different Immune Signatures in HPV- and HPV + Driven Human Head and Neck Squamous Cell Carcinoma, J Immunol Res 2022 (2022) 2079389.
6.
Lee YG, Kang EJ, Keam B, Choi JH, Kim JS, Park KU, Lee KE, Kwon JH, Lee KW, Kim MK, Ahn HK, Shin SH, Kim HR, Kim SB, Yun HJ. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01). BMC Cancer. 2020;20:813.PubMedPubMedCentralCrossRef
7.
Ribeiro IP, Caramelo F, Esteves L, Menoita J, Marques F, Barroso L, Miguéis J, Melo JB, Carreira IM. Genomic predictive model for recurrence and metastasis development in head and neck squamous cell carcinoma patients. Sci Rep. 2017;7:13897.PubMedPubMedCentralCrossRef
8.
Zhang X, Kiapour N, Kapoor S, Khan T, Thamilarasan M, Tao Y, Cohen S, Miller R, Sobel RA. Markovic-Plese, IL-11 induces encephalitogenic Th17 cells in multiple sclerosis and experimental autoimmune encephalomyelitis. J Immunol. 2019;203:1142–50.PubMedPubMedCentralCrossRef
9.
Seyedsadr M, Wang Y, Elzoheiry M, Shree Gopal S, Jang S, Duran G, Chervoneva I, Kasimoglou E, Wrobel JA, Hwang D, Garifallou J, Zhang X, Khan TH, Lorenz U, Su M, Ting JP, Broux B, Rostami A, Miskin D. Markovic-Plese, IL-11 induces NLRP3 inflammasome activation in monocytes and inflammatory cell migration to the central nervous system. Proc Natl Acad Sci U S A. 2023;120:e2221007120.PubMedPubMedCentralCrossRef
10.
11.
12.
Wang HQ, Fu R, Man QW, Yang G, Liu B, Bu LL. Advances in CAR-T cell therapy in Head and Neck squamous cell carcinoma. J Clin Med 12 (2023).
13.
14.
Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW. Gillison, Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856–67.PubMedPubMedCentralCrossRef
15.
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–65.PubMedCrossRef
16.
Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and cetuximab-refractory Head and Neck Cancer: results from a Single-Arm, phase II study. J Clin Oncol. 2017;35:1542–9.PubMedPubMedCentralCrossRef
17.
von Witzleben A, Wang C, Laban S, Savelyeva N, Ottensmeier CH. HNSCC: Tumour Antigens and Their Targeting by Immunotherapy, Cells 9 (2020).
18.
19.
20.
Tarique M, Naz H, Suhail M, Turan A, Saini C, Muhammad N, Shankar H, Zughaibi TA, Khan TH, Khanna N, Sharma A. Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy. Front Immunol. 2023;14:1138145.PubMedPubMedCentralCrossRef
21.
Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau J, Sun CM, Laurent-Puig P, Vano YA, Elaïdi R, Méjean A, Sanchez-Salas R, Barret E, Cathelineau X, Oudard S, Reynaud CA, de Reyniès A, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022;55:527–541e5.PubMedCrossRef
22.
Gavrielatou N, Vathiotis I, Economopoulou P, Psyrri A. The role of B cells in Head and Neck Cancer. Cancers (Basel) 13 (2021).
23.
Chen X, Yan B, Lou H, Shen Z, Tong F, Zhai A, Wei L, Zhang F. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis. Mol Immunol. 2018;96:28–36.PubMedCrossRef
24.
Lang Kuhs KA, Kreimer AR, Trivedi S, Holzinger D, Pawlita M, Pfeiffer RM, Gibson SP, Schmitt NC, Hildesheim A, Waterboer T, Ferris RL. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. Cancer. 2017;123:4382–90.PubMedCrossRef
25.
Dahlstrom KR, Anderson KS, Cheng JN, Chowell D, Li G, Posner M, Sturgis EM. HPV Serum Antibodies as predictors of Survival and Disease Progression in patients with HPV-Positive squamous cell carcinoma of the Oropharynx. Clin Cancer Res. 2015;21:2861–9.PubMedPubMedCentralCrossRef
26.
Wieland A, Patel MR, Cardenas MA, Eberhardt CS, Hudson WH, Obeng RC, Griffith CC, Wang X, Chen ZG, Kissick HT, Saba NF, Ahmed R. Defining HPV-specific B cell responses in patients with head and neck cancer. Nature. 2021;597:274–8.PubMedCrossRef
27.
Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA. Immune Landscape of viral- and carcinogen-driven Head and Neck Cancer. Immunity. 2020;52:183–199e9.PubMedPubMedCentralCrossRef
28.
29.
Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15:669–82.PubMedCrossRef
30.
de Miguel M, Calvo E. Clinical challenges of Immune Checkpoint inhibitors. Cancer Cell. 2020;38:326–33.PubMedCrossRef
31.
Yan Y, Zhang L, Zuo Y, Qian H, Liu C. Immune Checkpoint Blockade in Cancer Immunotherapy: mechanisms, clinical outcomes, and Safety profiles of PD-1/PD-L1 inhibitors. Arch Immunol Ther Exp (Warsz). 2020;68:36.PubMedCrossRef
32.
Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, Gutkind JS, Cohen EEW, Califano JA, Sharabi AB. B cells improve overall survival in HPV-Associated squamous cell carcinomas and are activated by Radiation and PD-1 blockade. Clin Cancer Res. 2020;26:3345–59.PubMedPubMedCentralCrossRef
33.
Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, Lampenfeld C, Atiya HI, Abecassis I, Kürten CHL, Qi Z, Soose R, Duvvuri U, Kim S, Oesterrich S, Lafyatis R, Coffman LG, Ferris RL, Vignali DAA, Bruno TC. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun. 2021;12:3349.PubMedPubMedCentralCrossRef
34.
Downs-Canner SM, Meier J, Vincent BG, Serody JS. B cell function in the Tumor Microenvironment. Annu Rev Immunol. 2022;40:169–93.PubMedCrossRef
35.
Wang Y, Schafer CC, Hough KP, Tousif S, Duncan SR, Kearney JF, Ponnazhagan S, Hsu HC, Deshane JS. Myeloid-derived suppressor cells impair B cell responses in Lung Cancer through IL-7 and STAT5. J Immunol. 2018;201:278–95.PubMedCrossRef
36.
Norouzian M, Mehdipour F, Balouchi Anaraki S, Ashraf MJ, Khademi B, Ghaderi A. Atypical memory and Regulatory B Cell subsets in Tumor draining Lymph nodes of Head and Neck squamous cell Carcinoma correlate with good prognostic factors. Head Neck Pathol. 2020;14:645–56.PubMedCrossRef
37.
Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother. 2004;27:273–81.PubMedCrossRef
38.
Wouters MCA, Nelson BH. Prognostic significance of Tumor-infiltrating B cells and plasma cells in Human Cancer. Clin Cancer Res. 2018;24:6125–35.PubMedCrossRef
39.
Viant C, Wirthmiller T, ElTanbouly MA, Chen ST, Cipolla M, Ramos V, Oliveira TY, Stamatatos L, Nussenzweig MC. Germinal center-dependent and -independent memory B cells produced throughout the immune response. J Exp Med 218 (2021).
40.
Hladíková K, Koucký V, Bouček J, Laco J, Grega M, Hodek M, Zábrodský M, Vošmik M, Rozkošová K, Vošmiková H, Čelakovský P, Chrobok V, Ryška A, Špíšek R, Fialová A. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells. J Immunother Cancer. 2019;7:261.PubMedPubMedCentralCrossRef
41.
Lechner A, Schlößer HA, Thelen M, Wennhold K, Rothschild SI, Gilles R, Quaas A, Siefer OG, Huebbers CU, Cukuroglu E, Göke J, Hillmer A, Gathof B, Meyer MF, Klussmann JP, Shimabukuro-Vornhagen A, Theurich S, Beutner D. Bergwelt-Baildon, Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. Oncoimmunology. 2019;8:1535293. von.PubMedPubMedCentralCrossRef
42.
Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Hacohen C, Rezvani K, Sharma P, Tetzlaff MT, Wang L. and J.A. Wargo, B cells and tertiary lymphoid structures promote immunotherapy response, Nature 577 (2020) 549–555.
43.
Zhou X, Su YX, Lao XM, Liang YJ, Liao GQ. CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells. Oral Oncol. 2016;53:27–35.PubMedCrossRef
44.
Shimamura T, Hashimoto K, Sasaki S. Feedback suppression of the immune response in vivo. II. Involvement of prostaglandins in the generation of suppressor-inducer B lymphocytes. Cell Immunol. 1982;69:192–5.PubMedCrossRef
45.
Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521:94–8.PubMedPubMedCentralCrossRef
46.
Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020;20:294–307.PubMedCrossRef
47.
Rosser EC, Mauri C, Regulatory B. Cells: origin, phenotype, and function. Immunity. 2015;42:607–12.PubMedCrossRef
48.
Khan TH, Srivastava N, Srivastava A, Sareen A, Mathur RK, Chande AG, Musti KV, Roy S, Mukhopadhyaya R, Saha B. SHP-1 plays a crucial role in CD40 signaling reciprocity. J Immunol. 2014;193:3644–53.PubMedCrossRef
49.
Han S, Feng S, Ren M, Ma E, Wang X, Xu L, Xu M. Glioma cell-derived placental growth factor induces regulatory B cells. Int J Biochem Cell Biol. 2014;57:63–8.PubMedCrossRef
50.
Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A. 2011;108:10662–7.PubMedPubMedCentralCrossRef
51.
Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, Spolski R, Poe JC, Leonard WJ, Tedder TF. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 2012;491:264–8.PubMedPubMedCentralCrossRef
52.
53.
Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH. Dieu-Nosjean, Tertiary lymphoid structures in cancers: Prognostic Value, Regulation, and manipulation for therapeutic intervention. Front Immunol. 2016;7:407.PubMedPubMedCentralCrossRef
54.
Mesin L, Ersching J, Victora GD. Germinal Cent B Cell Dynamics Immun. 2016;45:471–82.
55.
Li K, Guo Q, Zhang X, Dong X, Liu W, Zhang A, Li Y, Yan J, Jia G, Zheng Z, Tang W, Pan L, An M, Zhang B, Liu S, Fu B. Oral cancer-associated tertiary lymphoid structures: gene expression profile and prognostic value. Clin Exp Immunol. 2020;199:172–81.PubMedCrossRef
56.
Fridman WH. The tumor microenvironment: prognostic and theranostic impact. Recent advances and trends. Semin Immunol. 2020;48:101416.PubMedCrossRef
57.
Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are Associated with Tertiary lymphoid structures, cytolytic T-Cell responses, and Superior Prognosis in Ovarian Cancer. Clin Cancer Res. 2016;22:3005–15.PubMedCrossRef
58.
Wu Z, Zhou J, Xiao Y, Ming J, Zhou J, Dong F, Zhou X, Xu Z, Zhao X, Lei P, Huang T. CD20(+)CD22(+)ADAM28(+) B cells in Tertiary lymphoid structures promote Immunotherapy Response. Front Immunol. 2022;13:865596.PubMedPubMedCentralCrossRef
59.
Delvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, Gribben JG, Bombardieri M, Hodivala-Dilke K, Capasso M. Kocher, Pancreatic Cancer Chemotherapy is potentiated by induction of Tertiary lymphoid structures in mice. Cell Mol Gastroenterol Hepatol. 2021;12:1543–65.PubMedPubMedCentralCrossRef
60.
Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307–25.PubMedCrossRef
61.
Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9–22.PubMedCrossRef
62.
Fu Y, Tian G, Li J, Zhang Z, Xu K. An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation. Int J Mol Med. 2020;46:1501–13.PubMedPubMedCentral
63.
Jeske SS, Brand M, Ziebart A, Laban S, Doescher J, Greve J, Jackson EK, Hoffmann TK, Brunner C, Schuler PJ. Adenosine-producing regulatory B cells in head and neck cancer. Cancer Immunol Immunother. 2020;69:1205–16.PubMedPubMedCentralCrossRef
64.
Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell. 2014;25:809–21.PubMedPubMedCentralCrossRef
65.
Qin Z, Richter G, Schüler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4:627–30.PubMedCrossRef
66.
Hollern DP, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott KR, He X, Garay JP, Carey-Ewend K, Marron D, Ford J, Liu S, Vick SC, Martin M, Parker JS, Vincent BG, Serody JS, Perou CM. B cells and T Follicular Helper Cells Mediate Response to checkpoint inhibitors in high mutation Burden mouse models of breast Cancer. Cell. 2019;179:1191–1206e21.PubMedPubMedCentralCrossRef
67.
Siliņa K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng P, Curioni-Fontecedro A, Foukas P, Levesque MP, Moch H, Linē A. Van Den Broek, Germinal Centers Determine the prognostic relevance of Tertiary lymphoid structures and are impaired by corticosteroids in Lung squamous cell carcinoma. Cancer Res. 2018;78:1308–20.PubMedCrossRef
68.
Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18:842–59.PubMedCrossRef
69.
Liu Z, Fu YX. Chemother Induces Cancer-Fighting B Cells Cell. 2020;180:1037–9.
70.
Pezzotti N, Lelieveldt BPF, Van Der Maaten L, Hollt T, Eisemann E. Vilanova, approximated and user steerable tSNE for Progressive Visual Analytics. IEEE Trans Vis Comput Graph. 2017;23:1739–52.PubMedCrossRef
Metadata
Title
B cells in head and neck squamous cell carcinoma: current opinion and novel therapy
Authors
Xinyue Guo
Licheng Xu
Luan Nie
Chenyu Zhang
Yaohui Liu
Rui Zhao
Jing Cao
Linli Tian
Ming Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03218-3

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

LncRNA WFDC21P interacts with SEC63 to promote gastric cancer malignant behaviors by regulating calcium homeostasis signaling pathway

Research

Super enhancer related gene ANP32B promotes the proliferation of acute myeloid leukemia by enhancing MYC through histone acetylation

Research

PLK1 phosphorylates RhoGDI1 and promotes cancer cell migration and invasion

Review

Increasing the sensitivity and accuracy of detecting exosomes as biomarkers for cancer monitoring using optical nanobiosensors

Research

What role does GPR65 play in the progression of osteosarcoma? Its mechanism and clinical significance

Research

A cuproptosis score model and prognostic score model can evaluate clinical characteristics and immune microenvironment in NSCLC
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits